nadroparin

Action and Spectrum

Actions and Spectrum 

nadroparin works by inhibiting the activity of certain clotting factors in the blood, particularly factor Xa and thrombin.  

By inhibiting them, nadroparin helps to prevent the formation of new blood clots and stabilizes existing clots.

Drug Interaction

Adverse Reaction

Frequency not defined  

Venous thrombosis 

Skin necrosis 

Calcinosis 

Arterial thrombosis 

Thromboembolism  

Hypoaldosteronism  

Priapism 

Eosinophilia 

Increased serum alanine aminotransferase 

Hemorrhage 

Thrombocythemia 

Thrombocytopenia 

Increased serum aspartate aminotransferase 

Angioedema, hypersensitivity reaction 

Nonimmune anaphylaxis 

Injection site reaction 

Osteopenia 

Post marketing report  

Skin rash 

Urticaria  

Pruritus  

Erythema of skin 

Headache 

Migraine 

Black Box Warning

Black Box Warning 

None

Contraindication / Caution

Contraindication/Caution: 

Contraindication: 

• nadroparin should not be used in individuals who have a known hypersensitivity or allergy to drug and its components.  

Caution: 

• nadroparin should be used cautiously in patients undergoing surgery or other invasive procedures due to the risk of bleeding.  
• nadroparin should be used with caution in patients with liver disease, as the clearance of the drug may be affected. 
• nadroparin should be used with caution in patients with moderate to severe renal impairment.  

Pregnancy / Lactation

Pregnancy consideration: 

Pregnancy category: N/A 

Lactation: Excretion into human milk is unknown  

Pregnancy Categories:         

Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester. 

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.  

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women. 

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits. 

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women. 

Category N: There is no data available for the drug under this category. 

Pharmacology

Pharmacology  

nadroparin binds to antithrombin III (AT III), a natural anticoagulant in the body, and enhances its inhibitory effect on Factor Xa and thrombin.  

Pharmacodynamics 

nadroparin’s inhibition of thrombin helps stabilize existing blood clots and prevents them from growing. 

nadroparin has a mild inhibitory effect on platelet activation, which further contributes to its anticoagulant action. 

Pharmacokinetics 

Absorption   

nadroparin is absorbed into the bloodstream from the subcutaneous tissue.  

Distribution 

nadroparin circulates throughout the body, distributing to various tissues and organs. 

Metabolism 

nadroparin is not significantly metabolized by the body. Its primary mode of action is to bind to antithrombin III (ATIII) to exert its anticoagulant effect. 

Elimination and excretion 

The elimination of nadroparin primarily occurs through renal clearance.

Adminstartion

Administration 

nadroparin is a medication that is administered through subcutaneous injection.  

It available in the form of pre-filled syringes with a needle for injection.

Patient Information Leaflet

Patient information leaflet 

Generic Name: nadroparin 

Why do we use nadroparin? 

nadroparin is used to prevent deep vein thrombosis, which is the formation of blood clots in the deep veins.  

nadroparin is used as a preventive measure to reduce the risk of pulmonary embolism in high-risk patients.   

nadroparin is used as an anticoagulant during hemodialysis procedures to prevent clotting in the dialysis.